Introduction
Anxiety disorders (ADs) are the most prevalent psychiatric disorders in the elderly, although an onset in later life is uncommon [1] . As a result of conceptual and methodological differences between studies, prevalence rates differ widely. Most studies showed a prevalence of late-life ADs between 6 and 10 % [2] . Generalized anxiety disorder (GAD) is frequently cited as the most common AD in elderly; see e.g. [3, 4••] . However, the National Comorbidity Survey Replication (NCS-R) revealed social anxiety disorder and specific phobias as the most prevalent ADs across the life span, with a life-time prevalence in later life of 6.6 % and 7.5 %, respectively. Additionally, the prevalence rates in later life were 2.0 % for panic disorder (PD), 1.0 % for agoraphobia, 0.7 % for obsessive-compulsive disorder, 2.5 % for posttraumatic stress disorder, and 3.6 % for GAD [1] . Belonging to an older age group is a risk factor for not receiving adequate treatment [5] . This is associated with more disability, decline in functioning, reduced quality of life and increase of health care utilization; see e.g. [6] [7] [8] .
As less than 14 % of the older adults suffering from ADs are offered appropriate care [9] , it is obvious that there are major obstacles both in diagnosing and in treating these patients. Most elderly people with ADs tend to attribute their symptoms to physical causes [10] . Approximately 20 % of the elderly suffering from an AD consult health care services as a result of perceived dysfunctional anxiety symptoms [11] . General practitioners (GPs) have great difficulty recognizing the condition. Separating ADs from 'normal' anxiety induced by medical problems like cardiovascular or obstructive pulmonary diseases may be difficult [12, 13] . This is worrying as ADs are both more prevalent in and associated with increased complications in older adults with existing medical conditions [14, 15] . As GPs will likely be targeting diagnostic procedures for the somatic symptoms, which may also cover specific physical anxiety symptomatology, the diagnosis of a comorbid AD may easily be missed [16] [17] [18] [19] .
Additionally, the current generation of elderly may be less open in sharing psychological problems, as well as have a lack in necessary skills to recognize and verbalize anxiety symptoms compared to younger generations, and may therefore have been struggling with anxiety symptoms for many years without ever receiving adequate treatment [20] . This is partly complicated by their worries about stigmatization and reluctance to be referred to specialized mental health care [21] . Also, the level of agreement between targeted screening for anxiety and depression in older patients and the diagnostic findings of GPs is low [22, 23] . Chronic somatic comorbidity and the absence of earlier mental problems also decreases the chance of a proper diagnosis [16] [17] [18] 24] .
There has been extensive research into the management of ADs in populations aged between 18 and 65 years, which has led to evidence-based guidelines stipulating cognitive behavioral therapy (CBT) and antidepressants as the two treatments of choice. In addition, the few findings from randomized controlled trials (RCTs) focusing exclusively on elderly patients also tentatively indicated that both regimens may also be the optimal treatments for the management of latelife ADs; see e.g. [25, 26] . Although it was believed that CBT should be adapted to the specific needs of the elderly [27] , there is no or very little actual evidence for these assumptions. Two trials showed enhancement of CBT by age-specific adaptations for GAD in older adults [28, 29] . In essence, the adaptations referred to a distinct focus on education, a frequent use of reminders and repetition of the treatment rationale, offering frequent help with the homework assignments, and the exploitation of adherence enhancement strategies. Additionally, Wetherell and colleagues [30] found efficacy for a personalized type of CBT, modular CBT, which was adapted to the preferences of the elderly patient, compared to community enhancement in the treatment of late-life GAD. In one small study, acceptance and commitment therapy (ACT) was directly compared with CBT in the treatment of late-life GAD. Although there was no difference in efficacy between both treatments, ACT seemed more feasible for older GAD patients [31] . However, to date, there is no systematic research that has investigated which adaptations are needed to improve the effects of CBT for late-life ADs, nor studies that determined the extent to which modifications improve efficacy. However, as these trials were small and the adapted protocolized CBT was not directly compared to standard CB, except in one study [31] , these findings are premature. Moreover, although Gould and colleagues [32••] confirmed the efficacy of CBT in older adults with ADs, a lower efficacy compared to younger adults was suggested. Therefore, research into new treatment approaches, e.g. enhancement strategies, is urgently needed.
In stark contrast to the volume of RCTs testing pharmacological agents for major depression in later life, psychopharmacological interventions for late-life ADs have hardly been systematically studied. The data on late-life depression showed selective serotonin reuptake inhibitors (SSRIs) and tri-cyclic antidepressants (TCAs) to be comparably effective [33, 34] . Although the tolerability of both groups of agents was satisfactory, the classical TCAs (e.g. imipramine and clomipramine) were associated with significantly more side effects and dropout than the SSRIs (24 % vs. 18 %; [33, 35] ). As to the pharmacological treatment of late-life ADs, Pinquart and Duberstein [21] conducted a meta-analytic review of all available naturalistic studies and RCTs, and recommended antidepressants as the treatment of choice for late-life anxiety. The findings warrant a more balanced interpretation, however. Although all 23 reviewed studies tested pharmacological treatments, only four were RCTs evaluating specific late-life ADs. One of these showed venlafaxine to be superior to placebo in the treatment of late-life GAD [36] , while two reported large effect sizes for SSRIs in the management of mixed ADs [37, 38] , with the distinction that in these latter two trials over 70 % of the patients were diagnosed with GAD. And lastly, in the fourth study, both alprazolam and imipramine showed large effect sizes compared to placebo in the treatment of late-life PD. This was, however, a small-scale pilotstudy [39] . With a total number of 324 participants and cohorts ranging from 25 to 184 patients, the majority of these four RCTs were too small-scale to found the recommendations on. Recently, Gonçalves and Byrne published a meta-analysis of RCTs in late-life GAD and found similar efficacy in both pharmacological and psychological treatments [40••] . In the past six years, five more RCTs with pharmacological treatment in late-life ADs have appeared [41, 42•, 43-45] . Compared to placebo, efficacy was showed for duloxetine as well as quetiapine in latelife GAD [41, 44] , whereas both sertraline and buspirone were similar effective [45] . Both paroxetine and CBT were effective in the treatment of late-life PD [42• ]. Lenze and colleagues reported modest efficacy of escitalopram compared to placebo in late-life GAD [43] . Augmentation or combination studies of antidepressants and psychotherapy in late-life ADs are scarce. To date, one study showed enhanced response with modular CBT in the acute treatment phase of late-life GAD with escitalopram. At the long term, both escitalopram and CBT prevented relapse. Adding modular CBT to elderly GAD-patients with no or not sufficient response on escitalopram is a useful strategy in increasing response rates [4••] .
In contrast to guidelines, elderly patients are prescribed benzodiazepines three times more often compared to antidepressants (43 % versus 14 %, [9] ). Frequent use of prescription benzodiazepines is, however, associated with serious drug-related hazards, such as an increased risk of falls and fractures and possible aggravation of cognitive difficulties [46, 47] . But what are the underlying reasons for prescribing benzodiazepines, then? First of all, the agents are highly effective in the management of late-life anxiety [26] . Furthermore, many older adults resist the use of antidepressants based on a fear of dependence, prior negative experiences, a resistance to viewing their symptoms as a medical illness, and concern that antidepressants will prevent natural feelings [48] . Moreover, especially in older adults, the use of both SSRIs and TCAs is not without risk. The high prevalence of somatic syndromes such as cardiovascular diseases and arthrosis and the subsequent use of medications in this population increase the risk of interaction with SSRIs. The concurrent use of SSRIs and aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs), for example, raises the risk of gastrointestinal bleeding [49, 50] . Furthermore, previous findings showed that in elderly patients using either benzodiazepines or antidepressants the risk of falls and fractures was comparable; see e.g. [51••, 52] . Even the preferred SSRIs and other antidepressants (e.g. venlafaxine) showed a higher hazard ratio compared to the TCAs [51••] .
In conclusion, although CBT is effective in late-life ADs, the results of both protocolized CBTs and enhanced CBTs reported so far are modest, when compared with CBT outcome in younger adults. No differences were found between CBT and alternative psychological treatments in late-life GAD [32••, 40••, 53] . Differential age-effects are observed in the treatment of ADs, with a suggested lower efficacy in older adults; see e.g. [32••, 43, 54, 55•] . A major part of the mentioned RCTs, both psychological and pharmacological trials, were hampered by recruitment difficulties and high attrition rates (9 20-25 %) and concerned community-dwelling, relatively younger and relatively healthy participants. Research into the available psychopharmacological approaches to ADs to date indicates that the tolerability and effectiveness of antidepressants is comparable in younger and elderly adults. However, the benefits should be weighed carefully against the preferences of the elderly patients themselves, the relative risks of antidepressants, the severity of the anxiety symptoms, as well as the available alternative, behavioral approaches like CBT. Additionally, although preliminary, it is suggested that in late-life PD with a late disease onset or shorter duration of illness, CBT is to be preferred over paroxetine, whereas paroxetine might be the first choice in patients with an early onset and long duration of illness. [56] . Depending on the availability of CBT, in mild to moderate late-life ADs, CBT might be preferred compared to pharmacological treatment. In severe ADs, especially with comorbid depression, combined treatment with CBT and antidepressants is the first choice, with SSRIs as the preferred antidepressants. However, GAD is by far the most studied AD in later life. Evidence is predominantly limited to GAD, leaving most other anxiety syndromes underinvestigated, and thus preventing generalization of the results to "older" (e.g. 75-plus) elderly patients and populations suffering from specific ADs.
Treatment Diet and lifestyle
& Some lifestyle accommodations could be helpful in the management of late-life ADs.
-Responsible alcohol use.
-Engagement in social activities.
-Engagement in physical activities.
-Increasing self-reliance.
-Consuming healthy foods, avoiding fast food. Contraindications No absolute contraindications. 
Pharmacologic treatment

Main drug interactions
Serotonergic agonist-Buspirone
Standard dosage 5 mg/ day, increase by 5 mg per week to 10-15 mg/day on an administration regime of three times daily.
Contraindications Severe liver or kidney insufficiency, epilepsy.
Main drug interactions As inhibiting drugs of CYP3A4 (e.g. diltiazem, verapamil, itraconazole, erythromycin) may increase the plasma concentration of buspirone, the concurrent use of grapefruit juice has to be avoided. Decrease the dose of buspirone in the case of concurrent us of HIV-protease inhibitors or ketoconazole. Rifampicine potentiates the metabolization of buspirone.
Main side effects Dizziness, drowsiness, headache, nausea, perspiration, nervousness, agitation, sleep disturbance, confusion.
Special points Busprione is indicated for the treatment of GAD.
Tricyclic antidepressants (TCAs)
Standard dosage Table 2 contains the standard dosage of TCAs.
Contraindications Absolute contraindication is a recent myocardial infarction. Relative contraindications are urine retention, prostate hyperplasia, cardiovascular diseases and epilepsy. Main side effects Dry mouth, dizziness, constipation, sexual dysfunction, urinary problems, sweating, glaucoma, blurred vision, cognitive dysfunctioning, confusion, agitation, orthostatic hypotension, electro-cardiographic changes (e.g. abnormal QT interval), sedation, weight gain.
Main drug interactions
Special points Imipramine is indicated for the treatment of panic disorder; clomipramine is indicated for the treatment of obsessive compulsive disorder. 
Alternative psychological interventions
& Modular psychotherapy (MP) was developed as an alternative psychological treatment for late-life GAD. The rationale was to offer a more personalized type of psychotherapy for the typical heterogeneous older AD-patients in primary care, and to tailor it to specific symptoms and needs. MP includes psycho-education about the AD, monitoring symptoms, relaxation training, cognitive restructuring, thought stopping, exposure, behavioral activation, guidelines for improving sleep disturbance, problem-solving skills, life review, acceptance and mindfulness exercises, assertiveness training, time management, pain management and relapse prevention. Both therapist and patient discussed, according to a problem list, which modules were chosen. Patients received on average seven to eight modules. In one small study, MP was found effective compared with enhanced community treatment [30, class II] . & Acceptance and commitment therapy (ACT) focuses on accepting symptoms, noticing dysfunctional thoughts and emotions in a nonjudgmental way and increasing meaningful activities. In a small pilot study (n=16) with older GAD patients, ACT was compared with CBT. Both CBT and ACT were effective; however, 50 % of the CBT-patient dropped out, suggesting that ACT may be more feasible [31, class III].
Compliance with Ethics Guidelines
Conflict of Interest Gert-Jan Hendriks declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with animal subjects performed by the author.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:
Of major importance
